Trial
NCT01203930
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Chronic Lymphocytic Leukemia (CLL)
Intervention
Idelalisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-16